Silence Therapeutics plc
SLNCF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 70.5% | 45% | 41% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 72.7% | 59.3% | 46.8% | 39.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -113.2% | -196.2% | -289.3% | -365.9% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -104.7% | -170.5% | -231.4% | -317.4% |
| EPS Diluted | -0.33 | -0.49 | -0.52 | -0.44 |
| % Growth | 32.7% | 5.8% | -18.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |